Precede Biosciences
Mitra Miri currently serves as a Board Observer at Precede Biosciences and Normunity, while holding the position of Principal at Osage University Partners since October 2021. Prior roles include Investment Associate at Connecticut Innovations and Life Sciences Consultant at L.E.K. Consulting, where Miri advanced to Project Leader in the Healthcare Practice. Additional experience includes the Blavatnik Associate role at Yale Ventures and Business Analyst at Yale University's Office of the Provost, alongside a Fellowship at Canaan Partners and Flagship Pioneering. Notably, Miri contributed to the establishment of the first translational lab at the Infectious Diseases Institute. Miri holds a PhD in Neuroscience from Yale University.
This person is not in the org chart
This person is not in any teams
Precede Biosciences
1 followers
We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test uncovers actionable disease-defining transcriptional biology. Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma. By partnering with developers of new medicines and advancing our own diagnostic tests, we’re working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that’s precise to the biology of their disease.